At the same time, new medications, such as SGLT2 inhibitors and GLP-1 analogues or their combination, have a secondary weight loss effect, which can lead several patients to remission with minimal risk of hypoglycemia. The gene discussed is SLC5A2; the disease is Hypoglycemia.